Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching
To retrospectively investigate the biochemical outcome following delayed radiotherapy in patients with prostate cancer. From July 2000 to November 2008, 144 consecutive patients with localized prostate cancer underwent radiotherapy and androgen-deprivation therapy. Biochemical progression-free survi...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2013-04, Vol.33 (4), p.1629-1633 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1633 |
|---|---|
| container_issue | 4 |
| container_start_page | 1629 |
| container_title | Anticancer research |
| container_volume | 33 |
| creator | Nakayama, Hidetsugu Kanemoto, Ayae Kikuchi, Koji Matsuki, Katsuyuki Tomobe, Mitsuro Tsukamoto, Sadamu Takeshima, Hitoshi Oshiro, Yoshiko Sugahara, Shinji Tokuuye, Koichi |
| description | To retrospectively investigate the biochemical outcome following delayed radiotherapy in patients with prostate cancer.
From July 2000 to November 2008, 144 consecutive patients with localized prostate cancer underwent radiotherapy and androgen-deprivation therapy. Biochemical progression-free survival was compared in patients who began radiotherapy >6 months (delayed group) with these who began ≤ 6 months (non-delayed group) from diagnosis by biopsy. Treatment selection bias was adjusted by the propensity score method.
After a median follow-up of 64 months, the 5-year biochemical progression-free survival of the delayed and non-delayed groups was 87.4% (95% confidence interval, CI=69.7-95.1%) and 96.6% (95% CI=89.6-98.9%), respectively (p=0.03). Delayed radiotherapy was the only independent risk factor for biochemical progression (hazard ratio=3.97, 95% CI 1.07-14.7, p=0.04). The results were validated by propensity score analysis.
Delaying radiotherapy by >6 months increases the risk of biochemical progression in patients with localized prostate cancer. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1324958360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1324958360</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-293919e4ac57d3b558361a2860510a4256de912a280b958cb4cb1fa1704c6163</originalsourceid><addsrcrecordid>eNo1kE1LxDAYhIMg7rr6FyRHL4V8NGnjTdZPWPCy9_I2fetG2qYmqVJ_vV1cTwMzD8MwZ2TNC8OzQkm2IpcxfjCmtSnlBVkJqXResmJN3AN2MGNDAzTOpwMGGGfa-kBHSA6HFOm3SwfaeQud-1nAMfiYICG1MFgMd_RrCZoF9gOt52M84hBdmmm0PiDtIdmDG96vyHkLXcTrk27I_ulxv33Jdm_Pr9v7XTYKzlMmjDTcYA5WFY2slSql5iBKzRRnkAulGzRcLA6rjSptnduat8ALllvNtdyQ27_aZcjnhDFVvYsWuw4G9FOsuBS5OZayBb05oVPdY1ONwfUQ5ur_HfkLRzdg-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1324958360</pqid></control><display><type>article</type><title>Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nakayama, Hidetsugu ; Kanemoto, Ayae ; Kikuchi, Koji ; Matsuki, Katsuyuki ; Tomobe, Mitsuro ; Tsukamoto, Sadamu ; Takeshima, Hitoshi ; Oshiro, Yoshiko ; Sugahara, Shinji ; Tokuuye, Koichi</creator><creatorcontrib>Nakayama, Hidetsugu ; Kanemoto, Ayae ; Kikuchi, Koji ; Matsuki, Katsuyuki ; Tomobe, Mitsuro ; Tsukamoto, Sadamu ; Takeshima, Hitoshi ; Oshiro, Yoshiko ; Sugahara, Shinji ; Tokuuye, Koichi</creatorcontrib><description>To retrospectively investigate the biochemical outcome following delayed radiotherapy in patients with prostate cancer.
From July 2000 to November 2008, 144 consecutive patients with localized prostate cancer underwent radiotherapy and androgen-deprivation therapy. Biochemical progression-free survival was compared in patients who began radiotherapy >6 months (delayed group) with these who began ≤ 6 months (non-delayed group) from diagnosis by biopsy. Treatment selection bias was adjusted by the propensity score method.
After a median follow-up of 64 months, the 5-year biochemical progression-free survival of the delayed and non-delayed groups was 87.4% (95% confidence interval, CI=69.7-95.1%) and 96.6% (95% CI=89.6-98.9%), respectively (p=0.03). Delayed radiotherapy was the only independent risk factor for biochemical progression (hazard ratio=3.97, 95% CI 1.07-14.7, p=0.04). The results were validated by propensity score analysis.
Delaying radiotherapy by >6 months increases the risk of biochemical progression in patients with localized prostate cancer.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 23564807</identifier><language>eng</language><publisher>Greece</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - radiotherapy ; Aged ; Aged, 80 and over ; Androgen Antagonists - therapeutic use ; Disease Progression ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Outcome and Process Assessment (Health Care) - statistics & numerical data ; Prognosis ; Propensity Score ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - radiotherapy ; Retrospective Studies ; Survival Rate ; Time Factors</subject><ispartof>Anticancer research, 2013-04, Vol.33 (4), p.1629-1633</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23564807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakayama, Hidetsugu</creatorcontrib><creatorcontrib>Kanemoto, Ayae</creatorcontrib><creatorcontrib>Kikuchi, Koji</creatorcontrib><creatorcontrib>Matsuki, Katsuyuki</creatorcontrib><creatorcontrib>Tomobe, Mitsuro</creatorcontrib><creatorcontrib>Tsukamoto, Sadamu</creatorcontrib><creatorcontrib>Takeshima, Hitoshi</creatorcontrib><creatorcontrib>Oshiro, Yoshiko</creatorcontrib><creatorcontrib>Sugahara, Shinji</creatorcontrib><creatorcontrib>Tokuuye, Koichi</creatorcontrib><title>Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>To retrospectively investigate the biochemical outcome following delayed radiotherapy in patients with prostate cancer.
From July 2000 to November 2008, 144 consecutive patients with localized prostate cancer underwent radiotherapy and androgen-deprivation therapy. Biochemical progression-free survival was compared in patients who began radiotherapy >6 months (delayed group) with these who began ≤ 6 months (non-delayed group) from diagnosis by biopsy. Treatment selection bias was adjusted by the propensity score method.
After a median follow-up of 64 months, the 5-year biochemical progression-free survival of the delayed and non-delayed groups was 87.4% (95% confidence interval, CI=69.7-95.1%) and 96.6% (95% CI=89.6-98.9%), respectively (p=0.03). Delayed radiotherapy was the only independent risk factor for biochemical progression (hazard ratio=3.97, 95% CI 1.07-14.7, p=0.04). The results were validated by propensity score analysis.
Delaying radiotherapy by >6 months increases the risk of biochemical progression in patients with localized prostate cancer.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Disease Progression</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Outcome and Process Assessment (Health Care) - statistics & numerical data</subject><subject>Prognosis</subject><subject>Propensity Score</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Time Factors</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LxDAYhIMg7rr6FyRHL4V8NGnjTdZPWPCy9_I2fetG2qYmqVJ_vV1cTwMzD8MwZ2TNC8OzQkm2IpcxfjCmtSnlBVkJqXResmJN3AN2MGNDAzTOpwMGGGfa-kBHSA6HFOm3SwfaeQud-1nAMfiYICG1MFgMd_RrCZoF9gOt52M84hBdmmm0PiDtIdmDG96vyHkLXcTrk27I_ulxv33Jdm_Pr9v7XTYKzlMmjDTcYA5WFY2slSql5iBKzRRnkAulGzRcLA6rjSptnduat8ALllvNtdyQ27_aZcjnhDFVvYsWuw4G9FOsuBS5OZayBb05oVPdY1ONwfUQ5ur_HfkLRzdg-Q</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Nakayama, Hidetsugu</creator><creator>Kanemoto, Ayae</creator><creator>Kikuchi, Koji</creator><creator>Matsuki, Katsuyuki</creator><creator>Tomobe, Mitsuro</creator><creator>Tsukamoto, Sadamu</creator><creator>Takeshima, Hitoshi</creator><creator>Oshiro, Yoshiko</creator><creator>Sugahara, Shinji</creator><creator>Tokuuye, Koichi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching</title><author>Nakayama, Hidetsugu ; Kanemoto, Ayae ; Kikuchi, Koji ; Matsuki, Katsuyuki ; Tomobe, Mitsuro ; Tsukamoto, Sadamu ; Takeshima, Hitoshi ; Oshiro, Yoshiko ; Sugahara, Shinji ; Tokuuye, Koichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-293919e4ac57d3b558361a2860510a4256de912a280b958cb4cb1fa1704c6163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Disease Progression</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Outcome and Process Assessment (Health Care) - statistics & numerical data</topic><topic>Prognosis</topic><topic>Propensity Score</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakayama, Hidetsugu</creatorcontrib><creatorcontrib>Kanemoto, Ayae</creatorcontrib><creatorcontrib>Kikuchi, Koji</creatorcontrib><creatorcontrib>Matsuki, Katsuyuki</creatorcontrib><creatorcontrib>Tomobe, Mitsuro</creatorcontrib><creatorcontrib>Tsukamoto, Sadamu</creatorcontrib><creatorcontrib>Takeshima, Hitoshi</creatorcontrib><creatorcontrib>Oshiro, Yoshiko</creatorcontrib><creatorcontrib>Sugahara, Shinji</creatorcontrib><creatorcontrib>Tokuuye, Koichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakayama, Hidetsugu</au><au>Kanemoto, Ayae</au><au>Kikuchi, Koji</au><au>Matsuki, Katsuyuki</au><au>Tomobe, Mitsuro</au><au>Tsukamoto, Sadamu</au><au>Takeshima, Hitoshi</au><au>Oshiro, Yoshiko</au><au>Sugahara, Shinji</au><au>Tokuuye, Koichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2013-04</date><risdate>2013</risdate><volume>33</volume><issue>4</issue><spage>1629</spage><epage>1633</epage><pages>1629-1633</pages><eissn>1791-7530</eissn><abstract>To retrospectively investigate the biochemical outcome following delayed radiotherapy in patients with prostate cancer.
From July 2000 to November 2008, 144 consecutive patients with localized prostate cancer underwent radiotherapy and androgen-deprivation therapy. Biochemical progression-free survival was compared in patients who began radiotherapy >6 months (delayed group) with these who began ≤ 6 months (non-delayed group) from diagnosis by biopsy. Treatment selection bias was adjusted by the propensity score method.
After a median follow-up of 64 months, the 5-year biochemical progression-free survival of the delayed and non-delayed groups was 87.4% (95% confidence interval, CI=69.7-95.1%) and 96.6% (95% CI=89.6-98.9%), respectively (p=0.03). Delayed radiotherapy was the only independent risk factor for biochemical progression (hazard ratio=3.97, 95% CI 1.07-14.7, p=0.04). The results were validated by propensity score analysis.
Delaying radiotherapy by >6 months increases the risk of biochemical progression in patients with localized prostate cancer.</abstract><cop>Greece</cop><pmid>23564807</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2013-04, Vol.33 (4), p.1629-1633 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1324958360 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - radiotherapy Aged Aged, 80 and over Androgen Antagonists - therapeutic use Disease Progression Follow-Up Studies Humans Male Middle Aged Neoplasm Staging Outcome and Process Assessment (Health Care) - statistics & numerical data Prognosis Propensity Score Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - radiotherapy Retrospective Studies Survival Rate Time Factors |
| title | Delayed radiotherapy for patients with localized prostate cancer: validation by propensity score matching |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A18%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Delayed%20radiotherapy%20for%20patients%20with%20localized%20prostate%20cancer:%20validation%20by%20propensity%20score%20matching&rft.jtitle=Anticancer%20research&rft.au=Nakayama,%20Hidetsugu&rft.date=2013-04&rft.volume=33&rft.issue=4&rft.spage=1629&rft.epage=1633&rft.pages=1629-1633&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1324958360%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1324958360&rft_id=info:pmid/23564807&rfr_iscdi=true |